Loading clinical trials...
Loading clinical trials...
A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
Conditions
Interventions
Nab-paclitaxel
Gemcitabine
+1 more
Locations
17
United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
University of California - Davis Cancer Center
Sacramento, California, United States
University of Louisville - Brown Cancer Center
Louisville, Kentucky, United States
Weill Cornell Medical Center
New York, New York, United States
Martha Morehouse Tower
Columbus, Ohio, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Start Date
January 10, 2023
Primary Completion Date
March 28, 2025
Completion Date
March 28, 2025
Last Updated
April 16, 2025
NCT05691465
NCT04550494
NCT05673200
NCT06696768
NCT06311214
NCT06066138
Lead Sponsor
Theriva Biologics SL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions